These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32315746)

  • 1. Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.
    Jiang Y; Gao X; Singh ON; Zhang W; Agrahari V; Peet MM; Clark MR; Doncel GF; Banga AK
    Int J Pharm; 2020 May; 582():119342. PubMed ID: 32315746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
    J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
    Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
    Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
    Custodio JM; Fordyce M; Garner W; Vimal M; Ling KH; Kearney BP; Ramanathan S
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5135-40. PubMed ID: 27216057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
    Mandal S; Prathipati PK; Kang G; Zhou Y; Yuan Z; Fan W; Li Q; Destache CJ
    AIDS; 2017 Feb; 31(4):469-476. PubMed ID: 28121666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.
    Murakami E; Wang T; Park Y; Hao J; Lepist EI; Babusis D; Ray AS
    Antimicrob Agents Chemother; 2015; 59(6):3563-9. PubMed ID: 25870059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.
    Chua CYX; Jain P; Ballerini A; Bruno G; Hood RL; Gupte M; Gao S; Di Trani N; Susnjar A; Shelton K; Bushman LR; Folci M; Filgueira CS; Marzinke MA; Anderson PL; Hu M; Nehete P; Arduino RC; Sastry JK; Grattoni A
    J Control Release; 2018 Sep; 286():315-325. PubMed ID: 30092254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

  • 17. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
    Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
    J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
    Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
    Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.